Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 9, 2010, Pages 1341-1347

  Jian, Guo ^a   Songwen, Zhou ^a   Ling, Zhang ^a   Qinfang, Deng ^a   Jie, Zhang ^a   Liang, Tang ^a   Caicun, Zhou ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Epidermal growth factor receptor mutation; Non small cell lung cancer; PCR; Plasma; Pleural effusion

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLASMA; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEX DIFFERENCE; SMOKING; WILD TYPE; BLOOD; DISEASE COURSE; DRUG ANTAGONISM; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PREDICTION AND FORECASTING; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PLEURAL EFFUSION; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 77955486952     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0785-z     Document Type: Article

References (30)

1. S Bosari A Marchetti F Buttitta D Graziani G Borsani M Loda, et al. 1995 Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis Diagn Mol Pathol 4 249 255 10.1097/00019606- 199512000-00004 10.1097/00019606-199512000-00004 1:STN:280:DyaK287pt1Cntw%3D%3D 8634780
2. OS Breathnach B Freidlin B Conley MR Green DH Johnson DR Gandara, et al. 2001 Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results J Clin Oncol 19 1734 1742 1:STN:280:DC%2BD3M3gsl2ntw%3D%3D 11251004
3. Q Dong J Huang Y Zhou L Li G Bao J Feng, et al. 2002 Hematogenous dissemination of lung cancer cells during surgery; quantitative detection by flow cytometry and prognostic significance Lung Cancer 37 293 301 10.1016/S0169-5002(02)00102-2 10.1016/S0169-5002(02)00102-2 12234699
4. M Esteller M Sanchez-Cespedes R Rosell D Sidransky SB Baylin JG Herman 1999 Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small-cell lung cancer patients Cancer Res 59 67 70 1:CAS:528:DyaK1MXmsFOhug%3D%3D 9892187
5. X Fan FB Furnari WK Cavenee JS Castresana 2001 Non-isotopic silverstained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells Int J Oncol 18 1023 1026 1:CAS:528:DC%2BD3MXjsVSisbw%3D 11295051
6. M Fukuoka S Yano G Giaccone T Tamura K Nakagawa JY Douillard, et al. 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237 2246 10.1200/JCO.2003.10.038 10.1200/JCO.2003.10.038 1:CAS:528: DC%2BD2cXpsVGqu7w%3D 12748244
7. SW Han, et al. 2005 Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib J Clin Oncol 23 2493 2501 10.1200/JCO.2005.01.388 10.1200/JCO.2005.01. 388 1:CAS:528:DC%2BD2MXjvVyktL0%3D 15710947
8. H Kimura Y Fujiwara T Sone H Kunitoh T Tamura K Kasahara, et al. 2006 EGFR mutation status in tumor-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib Br J Cancer 95 1390 1395 10.1038/sj.bjc.6603428 10.1038/sj.bjc.6603428 1:CAS:528:DC%2BD28XhtF2ns77F 17060940
9. H Kimura K Kasahara M Kawaishi H Kunitoh T Tamura B Holloway, et al. 2006 Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer Clin Cancer Res 12 3915 3921 10.1158/1078-0432.CCR-05-2324 10.1158/1078-0432.CCR-05- 2324 1:CAS:528:DC%2BD28XmsValt7c%3D 16818687
10. H Kimura M Suminoe K Kasahara T Sone T Araya S Tamori, et al. 2007 Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) Br J Cancer 97 778 784 10.1038/sj.bjc.6603949 10.1038/sj.bjc.6603949 1:CAS:528:DC%2BD2sXhtVWksLzP 17848912
11. S Kobayashi TJ Boggon T Dayaram PA Jänne O Kocher M Meyerson, et al. 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786 792 10.1056/NEJMoa044238 10.1056/NEJMoa044238 1:CAS:528:DC%2BD2MXhsFCiurk%3D 15728811
12. T Kosaka Y Yatabe H Endoh H Kuwano T Takahashi T Mitsudomi 2004 Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 8919 8923 10.1158/0008-5472.CAN-04-2818 10.1158/0008-5472.CAN-04-2818 1:CAS:528:DC%2BD2cXhtVOmsL3P 15604253
13. MG Kris RB Natale RS Herbst TJ Lynch Jr D Prager CP Belani, et al. 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149 2158 10.1001/jama.290.16.2149 10.1001/jama.290.16.2149 1:CAS:528:DC%2BD3sXosVOnsbo%3D 14570950
14. EL Kwak R Sordella DW Bell N Godin-Heymann RA Okimoto BW Brannigan, et al. 2005 Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci USA 102 7665 7670 10.1073/pnas.0502860102 10.1073/pnas.0502860102 1:CAS:528:DC%2BD2MXkslOmsr0%3D 15897464
15. TJ Lynch DW Bell R Sordella S Gurubhagavatula RA Okimoto BW Brannigan, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 10.1056/NEJMoa040938 10.1056/NEJMoa040938 1:CAS:528: DC%2BD2cXktF2js7c%3D 15118073
16. A Marchetti C Martella L Felicioni F Barassi S Salvatore A Chella, et al. 2005 EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 857 865 10.1200/JCO.2005.08.043 10.1200/JCO.2005.08.043 1:CAS:528: DC%2BD2MXitVKit7o%3D 15681531
17. T Mitsudomi T Kosaka H Endoh Y Horio T Hida S Mori, et al. 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2513 2520 10.1200/JCO.2005.00.992 10.1200/JCO.2005.00.992 1:CAS:528:DC%2BD2MXjvVyktLs%3D 15738541
18. Moran T, Paz-Ares L, Isla D et al. (2007) High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients with poor performance status. In: ASCO annual meeting proceedings Part I, vol 25, No.18S, pp 7505
19. JG Paez PA Jänne JC Lee S Tracy H Greulich S Gabriel, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 10.1126/science.1099314 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D 15118125
20. G Pals K Pindolia MJ Worsham 1999 A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example Mol Diagn 4 241 246 10.1016/S1084-8592(99) 80027-7 10.1016/S1084-8592(99)80027-7 1:CAS:528:DyaK1MXnsVKjsbk%3D 10553024
21. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(13):306-311
22. DM Parkin 2001 Global cancer statistics in the year 2000 Lancet Oncol 2 533 543 10.1016/S1470-2045(01)00486-7 1:STN:280:DC%2BD387ntlCrtw%3D%3D 11905707
23. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al. (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl):2379-2385
24. M Sánchez-Céspedes M Monzó R Rosell A Pifarré R Calvo MP López-Cabrerizo, et al. 1998 Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients Ann Oncol 9 113 116 10.1023/A:1008230331221 10.1023/A:1008230331221 9541693
25. H Sasaki K Endo A Konishi M Takada M Kawahara K Iuchi, et al. 2005 EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler Clin Cancer Res 11 2924 2929 10.1158/1078-0432.CCR-04-1904 10.1158/1078-0432.CCR-04-1904 1:CAS:528:DC%2BD2MXjtlejt7o%3D 15837743
26. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson 2002 Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92 98 10.1056/NEJMoa011954 1:CAS:528:DC%2BD38Xkt1OlsQ%3D%3D 11784875
27. M Sonobe F Tanaka H Wada 2004 Lung cancer-related genes in the blood Ann Thorac Cardiovasc Surg 10 2l3 2l217
28. P Therasse SG Arbuck 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
29. CT Wittwer MG Herrmann AA Moss RP Rasmussen 1997 Continuous fluorescence monitoring of rapid cycle DNA amplification Biotechniques 22 130 138 1:CAS:528:DyaK2sXlsFWhsg%3D%3D 8994660
30. CC Zhou SW Zhou H Pan B Su ZQ Gao 2007 Detection of epidermal growth factor receptor mutations in non-small-cell lung cancer by rea1-time PCR using TaqMan-MGB probes Chin J Oncol 29 119 123